Delivery Order SPE2DB24D2101-SPE2DB25FKPKS
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $29,744.16 firm fixed price delivery order on July 28, 2025, for the supply of Rituxan Hycela (1,400 mg-23,400 11.7 mL), a monoclonal antibody immunosuppressant used in treating rheumatoid arthritis and certain lymphomas. This non-set-aside competitive award will be performed in Conshohocken, Pennsylvania, with an ultimate completion date of August 18, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $36,664.56, is for the delivery of Rituxan Hycela, a specialty medication, and does not have a set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which runs through December 2025....
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 1,400 mg-23,400 11.7 ml vials of the drug Rituxan Hycela, with a ceiling value of $74,092.00 and a completion date of June 7, 2023. The contract was awarded on May 16, 2023 and is a Firm Fixed Price Delivery Order with no set-aside designation, indicating open competition....
- This federal contract award (SPE2DB20D3103|SPE2DB22FM4X7) was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 1,400 mg-23,400 11.7 ml units of the drug Rituxan Hycela. The contract has a ceiling value of $11,738.44 and was awarded on a firm fixed-price basis, with a completion date of February 23, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant...
- The Defense Logistics Agency awarded a delivery order valued at $26,605.30 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Herceptin Hylecta 600mg injectable medication (10,000 5ml units). This firm fixed-price delivery order, which has no set-aside designation, will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025. The award represents a competitive procurement through the company's existing...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $42,647.60 on August 14, 2025, for the supply of Herceptin 150 mg vials, with a completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with the...
- The Defense Logistics Agency awarded a $39,673.94 delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vials on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is located in...
- The Defense Department's Medical Supply Chain, a division of the Defense Logistics Agency, awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Herceptin 150 mg vials. This firm fixed-price delivery order, valued at $26,704.20, is scheduled for completion by September 30, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. The award was competitively procured with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order on August 15, 2025, valued at $12,330.68 for the supply of Benlysta 200 mg/ml auto-injector medication. This is a firm fixed price, non-set-aside delivery order with a completion deadline of September 8, 2025, and represents a child contract under AmerisourceBergen's larger federal contract vehicle with DLA. The pharmaceutical product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $15,777.72 to AmerisourceBergen Drug Corp for the supply of Benlysta 400 mg vials. This contract, issued on August 21, 2025, with an ultimate completion date of September 12, 2025, is a firm fixed-price delivery order with no set-aside designation. The award was made competitively and represents a specific fulfillment requirement under AmerisourceBergen's larger federal contract vehicle supporting military healthcare procurement....
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKPKSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,327.94 to AmerisourceBergen Drug Corp for the supply of Rituxan Hycela (1,600 mg-26,800 13.4ml) on September 10, 2025, with completion expected by October 1, 2025. This competitively awarded, firm fixed-price delivery order is non-set-aside and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger prime vehicle with DLA. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 through December 2026 under the designation SPE2DX. This comprehensive global pharmaceutical support vehicle enables the company to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The current delivery order for Rituxan Hycela, a biologic medication used in cancer and autoimmune disease treatment, demonstrates AmerisourceBergen's ongoing role as a critical federal medical supply vendor within the military healthcare procurement ecosystem.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 9/10/25 |